Regeneron Pharmaceuticals rose after the company said it would acquire most of genetic testing company 23andMe’s assets out of bankruptcy for $256m. The deal excludes Lemonaid Health, the telehealth division of 23andMe.
Join our Mailing list!
Sign up to get all the latest financial news and business updates.
Please fill in the form and we will get in touch with you shortly and help answer any questions you may have about Offshore Supporting services.
